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Abstract
Background: Y-box binding protein-1 (YB-1) is the prototypic member of the cold shock protein
family that fulfills numerous cellular functions. In the nucleus YB-1 protein orchestrates
transcription of proliferation-related genes, whereas in the cytoplasm it associates with mRNA and
directs translation. In human tumor entities, such as breast, lung and prostate cancer, cellular YB-
1 expression indicates poor clinical outcome, suggesting that YB-1 is an attractive marker to predict
patients' prognosis and, potentially, is suitable to individualize treatment protocols. Given these
predictive qualities of YB-1 detection we sought to establish a highly specific monoclonal antibody
(Mab) for diagnostic testing and its characterization towards outcome prediction (relapse-free and
overall survival).
Methods: Hybridoma cell generation was carried out with recombinant YB-1 protein as
immunogen and Mab characterization was performed using immunoblotting and ELISA with
recombinant and tagged YB-1 proteins, as well as immunohistochemistry of healthy and breast
cancer specimens. Breast tumor tissue array staining results were analyzed for correlations with
receptor expression and outcome parameters.
Results: YB-1-specific Mab F-E2G5 associates with conformational binding epitopes mapping to
two domains within the N-terminal half of the protein and detects nuclear YB-1 protein by
immunohistochemistry in paraffin-embedded breast cancer tissues. Prognostic evaluation of Mab F-
E2G5 was performed by immunohistochemistry of a human breast cancer tissue microarray
comprising 179 invasive breast cancers, 8 ductal carcinoma in situ and 37 normal breast tissue
samples. Nuclear YB-1 detection in human breast cancer cells was associated with poor overall
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BMC Cancer 2009, 9:410 http://www.biomedcentral.com/1471-2407/9/410survival (p = 0.0046). We observed a close correlation between nuclear YB-1 detection and
absence of progesterone receptor expression (p = 0.002), indicating that nuclear YB-1 detection
marks a specific subgroup of breast cancer. Likely due to limitation of sample size Cox regression
models failed to demonstrate significance for nuclear YB-1 detection as independent prognostic
marker.
Conclusion: Monoclonal YB-1 antibody F-E2G5 should be of great value for prospective studies
to validate YB-1 as a novel biomarker suitable to optimize breast cancer treatment.
Background
Since the seminal description of Janz et al. [1] that high
YB-1 expression levels in breast cancer and surrounding
tissues are indicative for poor outcome, follow-up studies
have extended these findings to larger cohorts and other
cancer entities, including non-small cell lung cancer [2],
ovarian cancer [3], prostate cancer [4], and synovial sar-
coma [5]. A recent study confirmed the unfavorable out-
come of patients with YB-1 expression in breast cancer
tissue with a large cohort of 4049 cases over an observa-
tion period of 20 years, which reached statistical signifi-
cance in nearly all subgroups [6]. Furthermore, Bargou et
al. [7] reported that nuclear localization of YB-1 was asso-
ciated with P-glycoprotein expression in human primary
breast cancers, other studies have shown a co-expression
of YB-1 and P-glycoprotein in osteo- and synovial sar-
coma as well as breast, ovarian and prostate cancer [3,5,8-
11].
Cold-shock proteins like the Y-box binding (YB) protein
fulfill pleiotropic functions, e.g. regulation of target genes,
(pre-)mRNA splicing and translation [12-16]. YB-1 is a
multifunctional protein with fascinating roles in cell biol-
ogy. First and utmost, YB-1 serves multiple roles in gene
transcription with numerous target genes involved in
DNA replication and proliferation [17-22]. Overexpres-
sion of YB-1 via a transgene in a mouse model induced the
development of breast cancers of many histological types
[23], suggesting that YB-1 is oncogenic. Reports confirm
the relevance of YB-1 expression for EGF-independent
breast cancer cell growth [24]. Following its original clon-
ing as binding activity of the EGF receptor promoter [25],
Dunn et al. recently reported that YB-1 is a strong trans-
stimulator of EGF receptor expression in breast cancer
cells [26].
A predominant nuclear localization of YB-1 protein goes
along with intrinsic expression of putative oncogenes
[1,4,24,27], response to oxidative stress and coordination
of DNA excision repair [28]. On the other hand, there is
evidence for a prominent role of YB-1 as RNA-binding
molecule and constituent of cytoplasmic major messenger
ribonucleoprotein particles (in this context denoted p50)
[29,30]. Studies addressing the question what regulates
YB-1 expression, its subcellular localization and potential
protein modifications have shed some light on underlying
mechanisms. The transcription of YB-1 is upregulated by
basic helix-loop-helix transcription factor Twist [31].
Twist itself is an immediate target of signal tranducers and
activator of transcription (STAT)-3, which may be activated
by epidermal growth factor receptor signaling [32]. Knock-
down of YB-1 completely abrogated the proliferative effect
of Twist, emphasizing the fundamental role that YB-1
plays for the EGF receptor axis. Furthermore, serine 102 of
YB-1 protein is a direct target of protein kinases B (AKT)
and RSK [33], both of which are signaling cascades
involved in cell transformation, proliferation and anchor-
age-independent growth [17,27,34].
A general evaluation of YB-1 expression in breast cancer
patients is limited due to lack of a suitable antibody of
unrestricted quantity and defined quality, preferably
monoclonal. This could potentially allow to diversify
their relative risk profile and chemotherapy sensitivity
[7,35]. Furthermore, most polyclonal antibodies, like the
ones used for breast cancer tissue by Janz et al. [1] and
Habibi et al. [6], predominantly detect YB-1 in the cyto-
plasm, whereas YB-1 protein activities relating to chromo-
somal instability and gene regulation must take place
within the nuclear compartment [36].
In the following we present data on a newly established
monoclonal YB-1 antibody that is characterized as suita-
ble for immunohistochemistry in paraffin-embedded tis-
sue. The expression of YB-1 by means of this antibody was
analyzed by immunohistochemistry in a cohort of breast
cancer specimens. For all tumour specimens analyzed, full
histopathological and clinical follow-up data were availa-
ble, allowing uni- and multivariate analyses of nuclear YB-
1 expression in correlation to well-established factors of
breast cancer prognosis (grade, nodal status, HER2, estro-
gen receptor (ER) status, progesterone receptor (PR) sta-
tus). Thereby we characterized the Mab as a novel tool
that can be used in breast cancer prognosis and therapy
stratification.
Methods
Mab generation
Mouse work was in full compliance with the guidelines
for animal care and was approved by the animal care com-Page 2 of 17
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immunized by intraperitoneal and intravenous injection
of 100 μg recombinant YB-1 full-length protein emulsi-
fied in equal volume of Freund's adjuvant (Gibco-BRL life
technologies, Karlsruhe, Germany) followed by a booster
injection six weeks later containing 10 μg of antigen in
Freund's adjuvant. The response was assessed by dot blot
assay with recombinant YB-1 protein. Three days after the
last booster injection, spleen cells were obtained and
fused with X63-Ag/653 (BALB/c) mouse myeloma cells
and propagated according to standard procedures. The
fused cells were resuspended in DMEM medium (Gibco
BRL life technologies) supplemented with 10% bovine
calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin,
50 μM hypoxanthine, 160 μM thymidine, and 400 nM
aminopterin. Aliquots of the cell suspension (100 μl)
were dispensed into 96-well plates and incubated at
37°C/5% CO2. Every week the medium was replaced with
fresh selection medium supplemented with recombinant
interleukin-6 (100 U/ml). After two weeks the medium
was replaced by HT-medium (DMEM medium (Gibco
BRL life technologies) supplemented with 10% bovine
calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin,
100 μM hypoxanthine and 160 μM thymidine and
another week later cells were cultured in standard DMEM
medium (4500 mg/l D-Glucose supplemented with
GlutaMax (Gibco BRL life technologies) with 10% bovine
calf serum, 100 U/ml penicillin and 100 μg/ml streptomy-
cin. Hybridoma supernatants from 96-well plates were
screened by dot blot assay with recombinant YB-1 protein
for specific antibody synthesis. The positive-tested hybrid-
oma cells were single-cell cloned twice by limited dilution
in standard medium as described [37]. Immunoglobulins
in the hybridoma cell culture supernatants were purified
using protein A sepharose or protein G sepharose col-
umns according to the immunoglobulin isotype
(ÄKTAFPLC systems, Amersham Biosciences, Freiburg, Ger-
many). F-E2G5 was of IgG2b isotype. Purified monoclonal
antibodies were conjugated to biotin as described [38].
Plasmids, cell line and transfection
Plasmids encoding for GFP and YB-1-GFP fusion proteins
(pcDNA6/V5-His-YB-1-GFP) have been described previ-
ously [20]. HEK293T cells were cultured in DME-medium
containing 10% fetal bovine serum, 100 U/ml penicillin,
100 μg/ml streptomycin and 2 mM L-glutamine. Tran-
sient transfections of HEK293T cells with vectors were per-
formed by means of calcium phosphate precipitation
methodology using purified endotoxin-free plasmid DNA
preparations. HEK293T cells expressing the respective
proteins were harvested 48 h after transfection and cyto-
plasmic and nuclear fractions were prepared by cell lysis
in buffer A (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10
mM KCl, 0.2 mM PMSF, 1 mM sodium vanadate, 0.5 mM
DTT) for 10 min on ice, followed by centrifugation at
2.000 rpm for 1 minute. The supernatant corresponds to
soluble cytoplasmic proteins and contains GFP and YB-1-
GFP proteins.
Western Blotting
SDS-PAG electrophoresis was performed with protein
extracts containing GFP or YB-1-GFP protein under reduc-
ing and non-reducing conditions. Proteins were separated
on 12% SDS-PAG and transferred to nitrocellulose mem-
branes (Schleicher-Schuell, Dassel, Germany). Mem-
branes were blocked in TTBS (10 mM Tris-HCl [pH 8.0],
150 mM NaCl, 0.2% Tween-20) containing 5% non-fat
dry milk for 1 h at room temperature. After three washing
steps in TTBS, blots were incubated with biotin-labeled
YB-1 Mab F-D2G5 diluted 1:2,000 and StreptABComplex
diluted 1:50 (DAKO Cytomation, Glostrup, Denmark)
was added. Following two more washes in TTBS the per-
oxidase reaction was visualized by ECL system (Amer-
sham, Freiburg, Germany). Immunoprecipitation
experiments were performed with the indicated antibod-
ies that were incubated with pre-cleared pansorbin.
ELISA
Recombinant YB-1 protein was expressed in E. coli and
affinity purified as previously described [39]. For ELISA
96-well polystyrene plates were incubated with 200 μl of
recombinant YB-1 protein solution (3 ng/μl) in coating
buffer (15 mM Na2CO3, 35 mM NaHCO3) overnight at
4°C. After four washing steps with phosphate-buffered
saline with 0.05% Tween-20 (50 mM sodium phosphate,
3 mM potassium phosphate, 150 mM sodium chloride
[pH 7.4]), blocking with 2.5% low fat milk powder in PBS
was performed at 37°C for 1 h. After four additional
washing steps Mabs dissolved in washing buffer at 1:50
were added to each well (200 μl) and incubated another
hour at 37°C and washed four times. Bound Mabs were
detected either by incubation with 100 μl HRP-conju-
gated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/
Tween (non-biotin-labelled Mabs) or by incubation with
100 μl StrepABComplex diluted 1:50 (DAKO Cytoma-
tion, Glostrup, Denmark) with biotin-labelled Mabs for 1
h at 37°C and developed with ABTS (2,2'-azino-di-3-
ethylbenzthiazoline-6-sulfonic acid)/H2O2. One row was
used as blank containing immobilised YB-1 protein but
with no addition of Mabs.
Immunohistochemistry
Immunohistochemistry was performed as described
recently [40] using an established breast tissue microarray
[41]. The breast tissue samples of this tissue microarray
were obtained from patients treated by primary surgery
for breast cancer at the Department of Gynecology, Uni-
versity Hospital Regensburg, Germany, with institutional
review board approval. All patients gave informed consent
to the study for retention and analysis of their tissue forPage 3 of 17
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ized and rehydrated, and the endogenous peroxidase
activity was quenched by treatment with 3% H2O2. Anti-
gen retrieval was performed by pretreatment in citrate
buffer [pH 6.0] in a microwave oven (three times for 8
minutes at 600 W). Slides were incubated with a 1:25
dilution of monoclonal biotin-labeled YB-1 antibody in
2% milk powder dissolved in PBS in a humidified cham-
ber overnight at 4°C. After another wash Vectastain avi-
din-biotin complex (Vector Laboratories, California,
USA) was added for 10 minutes. Immunostaining was vis-
ualized using 3,3'-diaminobenzidine tetrahydrochloride
(DAB, Sigma, Deisenhofen, Germany) and hydrogen per-
oxide for 5 minutes. Finally, sections were counterstained
with Mayer's hematoxylin. The primary antibody was
omitted for negative controls. Tissue microarray slides
were analyzed by a pathologist without knowledge of
clinicopathological parameters of the tumors. Nuclear YB-
1 staining was simply scored as positive (1) or negative
(0), depending on visual inspection of tumor nuclei
under high magnification (400×). The decision to score
the staining pattern according to a dichotomous crite-
rium, nuclear versus non-nuclear staining seemed justi-
fied as the pattern was evident throughout all specimens.
There was no tissue with restricted focal nuclear staining.
Cytoplasmic YB-1 staining was scored according to the
immunoreactivity score (IRS) system developed by Rem-
mele and Stegner [42], subsequently tumors were grouped
into low expressers (IRS 0-3) and high expressers (IRS 4-
12). For comparison of the F-E2G5 tissue staining pattern
with peptide-derived affinity-purified YB-1 antibodies,
the following antibodies were utilized: YB-1#1 has been
generated by immunization and purification with a pep-
tide corresponding to an N-terminal YB-1 epitope and was
purchased from antibodies-online; YB-1#2 has been
described by Janz et al. [1])
Statistical analyses of tissue microarray data
Statistical analyses were performed with SPSS version 17.0
(SPSS, Chicago, IL). Differences were considered statisti-
cally significant when p < 0.05. Contingency table analy-
ses and two-sided Fisher's exact tests were used to study
the statistical association between clinicopathologic and
immunohistochemical variables. Recurrence-free and dis-
ease-specific survival curves comparing patients with or
without any of the factors were calculated using the Kap-
lan-Meier method, with significance evaluated by two-
sided log-rank statistics. Disease-specific survival and
recurrence-free survival were measured from time of sur-
gery. For the analysis of recurrence, patients were censored
at the time of their last tumor-free clinical follow-up
appointment. For disease-specific survival analysis,
patients were censored at the time of their last tumor-free
clinical follow-up appointment or at their date of death
not related to the tumor. A stepwise multivariable Cox
regression model was adjusted, testing the independent
prognostic relevance of nuclear YB-1 immunoreactivity.
The limit for reverse selection procedures was p = 0.01.
The proportionality assumption for all variables was
assessed with log-negative-log survival distribution func-
tions.
Multiple logistic regression model
Regression analyses were conducted with R 2.8 (r-
project.org). The binary response variable y is regressed on
the explanatory variables, x1, x2, ..., xq. The model for n
observations is defined by ln(p/(1-p)) = Xβ + ε, where ε
contains the residual error terms and p = Pr(y = 1). The
parameters are estimated by maximum likelihood estima-
tion. The regression coefficients β1, β2, ..., βq give the
change in the response variable corresponding to a unit
change in the appropriate explanatory variable, condi-
tional on the other variables remaining constant. The
intercept corresponds to the expected value of the
response variable y when all the explanatory variables are
zero. Significance tests of whether the coefficients take the
value zero can be derived on the assumption that for a
given set of values of the explanatory variables, y has a
normal distribution with constant variance. The data was
centered and scaled previous to applying logistic regres-
sion. Centering is performed by subtracting the column
means (omitting missing values) of x from their corre-
sponding columns, and scaling is done by dividing the
(centered) columns of x by their root-mean-square.
Explanatory variables were considered statistically signifi-
cant when P < 0.05.
Results
Characterization of monoclonal YB-1-specific antibody F-
E2G5
In a first approach the F-E2G5 antibody was examined for
its substrate specificity by western blot analysis using cell
extracts from HEK293 cells expressing GFP, YB-1-GFP or
YB-1(21-147)-GFP proteins. GFP and YB-1-GFP fusion
protein expression was ascertained by detection with
monoclonal GFP antibody (Figure 1A, lanes 1-3). Immu-
noblotting with biotinylated F-E2G5 Mab was performed
following addition of non-reducing (lanes 4-6) or reduc-
ing buffer (lanes 7-8) to protein samples. Mab F-E2G5
detects full-length YB-1-GFP fusion protein and also the
truncated protein encompassing amino acids 21-147.
However, detection succeeds only with non-reducing
buffer and not under reducing buffer conditions with
inclusion of mercaptoethanol (Figure 1A, compare lanes
5 and 7). Endogenous YB-1 protein with a relative molec-
ular weight of 50 kDa was not detected by immunoblot-
ting using F-E2G5 antibody, neither in denaturing nor in
non-denaturing gels (data not shown). These results indi-
cate that (i) the epitope(s) recognized by F-E2G5 resides
within the YB-1 protein domains aa21-147 and (ii) detec-Page 4 of 17
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western blotting.
One may conclude that the GFP-tag stabilizes the YB-1
protein conformation and permits successful detection by
means of Mab F-E2G5, as the endogenous YB-1 protein
from cell lysates (~50 kDa) was not detected by western
blotting (only minute amounts were immunopositive fol-
lowing prolonged exposure). To ensure that Mab F-E2G5
successfully binds YB-1 protein under non-reducing and
Detection of YB-1-GFP and YB-1(21-147)-GFP by immunoblot and recombinant YB-1 by ELISAFigure 1
Detection of YB-1-GFP and YB-1(21-147)-GFP by immunoblot and recombinant YB-1 by ELISA. (A) HEK293T 
cell extracts containing GFP (lanes 1 and 4), YB-1-GFP (lane 2, 5 and 7) or YB-1(21-147)-GFP proteins (lanes 3, 6 and 8) were 
separated in denaturing gels and following transfer to nitrocellulose probed with GFP antibody (lanes 1 to 3) or Mab F-E2G5 
(lanes 4 to 8). Relative mobilities of expressed proteins are indicated by arrowheads. Notably, reducing sample buffer prevents 
detection of tagged YB-1 proteins by immunoblot (lanes 7 and 8). (B) ELISA was performed by coating with recombinant affin-
ity purified hexahistidin-tagged YB-1 protein. Biotin-labeled Mab F-E2G5 yields an even stronger signal than non-biotinylated 
Mab. Controls included omission of antibody (Con1) or antigen (Con2).
recomb. YB-1
*Page 5 of 17
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direct ELISA with recombinant, affinity-purified YB-1 pro-
tein expressed in E. coli. Biotinylated as well as non-bioti-
nylated Mabs F-E2G5 were tested. Under both conditions
recombinant YB-1 protein was detected (Figure 1B), even
better with biotinylated Mab F-E2G5. Controls included
omission of antibody (Con1) or antigen (Con2) and
addition of irrelevant IgG2/irrelevant biotinylated IgG2
antibody (not shown), all yielding negative results. Thus,
Mab F-E2G5 binds epitope(s) that reside within YB-1 pro-
tein domains aa21 to 147. In addition, a sandwich ELISA
was established with a series of GFP-tagged fusion pro-
teins that include the following domains of YB-1 protein:
aa21-147, aa146-317, aa146-225, aa146-172, aa260-317,
aa146-262, aa21-262. Biotinylated Mab F-E2G5 was able
to detect all fusion proteins that encompassed aa146-172.
ELISA results were scored positive with an optical density
of >0.4, whereas background values were below 0.05.
These results support the notion that two distinct confor-
mational epitopes are recognized by the Mab, one within
the N-terminal (aa21-147) and one within the centrally
localized domains (aa146-172).
To further evaluate the propensity of Mab F-E2G5 to asso-
ciate with YB-1-GFP or endogenous YB-1 proteins Mab F-
E2G5 was evaluated in immunoprecipitation studies (Fig-
ures 2A and 2B). Mab F-E2G5 successfully pulled down
YB-1-GFP, that was subsequently detected by monoclonal
anti-GFP-tag antibody (Figure 2A). Furthermore Mab F-
E2G5 immunoprecipitated endogenous YB-1 protein
from HEK293 whole cell extracts, with immunoprecipi-
tated protein being detected by polyclonal peptide-
derived anti-YB-1 antibody directed against the protein C-
terminus (denoted YB-1(C-term), Figure 2B, lane 2).
Immunoprecipitation studiesFigure 2
Immunoprecipitation studies. (A) Control IgG1, F-E2G5 and anti-GFP-tag antibodies were added to binding reactions with 
YB-1-GFP protein. Immunoblotting (IB) was carried out with anti-GFP antibody. (B) HEK293 cell protein extracts containing 
endogenous YB-1 protein were incubated with control IgG1, F-E2G5 and polyclonal anti-YB-1(C-term) antibodies and immu-
noprecipitated using pansorbin. Detection of protein pull-down was accomplished by immunoblotting with anti-YB-1(C-term) 
antibody. Sample buffers utilized were reducing (left) or non-reducing (right). Recombinant YB-1 protein was run aside w/o 
immunoprecipitation to visualize relative mobilities. "*" indicated mobilities of immunoglobulin heavy and light chains.
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precipitated by polyclonal anti-YB-1(C-term) immunob-
lotting was unsuccessful under reducing conditions
(Figure 2B, lane 3).
Next immunoprecipitated proteins were loaded on gels in
non-reducing buffer (omission of mercaptoethanol and
EDTA). Under these conditions immunoprecipitated
endogenous YB-1 pulled down by monoclonal F-E2G5
antibody was no longer detected with polyclonal anti-YB-
1(C-term) antibody. Successful immunoprecipiation by
anti-YB-1(C-term) antibody was however possible (Figure
2B, lane 8). Heavy and light chains from immunoglobu-
lins, that are contaminants from the immunoprecipita-
tion procedure, were detected in samples loaded under
non-reducing buffer conditions (indicated by "*" in Fig-
ure 2B).
From these results it is concluded that monoclonal F-
E2G5 antibody has the propensity to immunoprecipitate
YB-1-GFP as well as endogenous YB-1 protein, however,
detection by means of immunoblotting with the utilized
polyclonal anti-YB-1 antibody is susceptible to the chosen
buffer conditions.
Mab F-E2G5 is suitable for YB-1 immunodetection in 
formalin-fixed paraffin-embedded breast cancer tissue
From our previous studies it was clear that the fixation
procedure markedly affects detection of YB-1 in rat tissue
[43]. In the following we performed immunohistochem-
istry of sequential tissue sections from patients diagnosed
with invasive breast cancer. Biotinylated Mab F-E2G5 and
two polyclonal peptide-derived YB-1 antibodies generated
against distinct epitopes within the protein N-terminus
were utilized. Notably, one of the polyclonal antibodies
used (YB-1#2) has been previously applied by Janz et al.
[1], the other is commercially available (YB-1#1; see Mate-
rials). Sequential sections were stained for Ki67 to identify
cycling cells and exclude the possibility that biotinylated
Mab F-E2G5 merely detects such cells. As can be seen in
Figure 3 there was strong cytoplasmatic staining of cancer-
ous cells with both polyclonal antibodies (#1 and #2).
The overall pattern of immunopositive cells was similar
with the Mab, however, a considerable fraction of cells
exhibited strong nuclear staining. Ki67 positivity was
observed in about 10 to 25% of all tumor cells, which was
considerably lower than YB-1 positive cells detected by
Mab F-E2G5. This finding excludes the possibility that the
Mab only detects cycling cells.
From these results we conclude that the established Mab
F-E2G5 is suitable for immunohistochemistry with for-
malin-fixed paraffin-embedded tissue, as routinely per-
formed for histological analyses. The overall staining
pattern with Mab and polyclonal antibodies is similar.
However, Mab F-E2G5 preferentially detects nuclear YB-1.
Nuclear YB-1 staining pattern in breast cancer tissue
Immunohistochemical analysis was used to investigate
YB-1 protein expression in normal breast tissue and breast
cancers. We analyzed a tissue microarray with 224 breast
tissue samples, i.e. 179 invasive ductal carcinomas, eight
ductal carcinoma in situ (DCIS) and 37 normal breast tis-
sue samples. To our knowledge, the latter group is larger
than all other control groups analyzed by immunohisto-
chemistry for YB-1 expression so far. Nuclear YB-1 immu-
nohistochemical staining was only detectable in invasive
ductal carcinomas, but not in DCIS and normal breast tis-
sue. Figure 4 shows representative images of YB-1 expres-
sion in normal and malignant breast tissues. YB-1 staining
was not detectable in normal breast tissue (Figures 4A and
4B). In DCIS (Figures 4C and 4D) cytoplasmic YB-1
expression was present in 75% (6/8) of cases, while
nuclear YB-1 expression was not present. Invasive ductal
carcinomas exhibited nuclear staining in 24% (43/179) of
cases (Figures 4E and 4F).
YB-1 expression, clinico-pathological parameters and 
patient survival
Clinicopathologic and immunohistochemical characteris-
tics were correlated with nuclear and cytoplasmic YB-1
staining for descriptive data analysis (Table 1). Cytoplas-
mic YB-1 expression detected with the Mab F-E2G5 was
not significantly correlated to overall (p = 0.134) and
recurrence-free survival (p = 0.39).
However, nuclear YB-1 expression detected by antibody F-
E2G5 was associated with shorter overall survival (OS; p =
0.0046) and exhibited a strong trend towards association
with shorter recurrence-free survival (RFS; p = 0.09). These
were compared by Kaplan Meier analysis between inva-
sive breast tumours with nuclear YB-1 expression versus all
other invasive breast tumours exhibiting no nuclear
expression (Figure 5). Patients with nuclear YB-1 expres-
sion in the tumor had an estimated mean OS of 90
months (95% confidence interval (CI): 72-109 months)
compared to 117 months (95% CI: 108-126 months) in
patients with absent nuclear YB-1 immunoreactivity.
Nuclear YB-1 detection also correlated with tumor stage
(p = 0.004), higher (G2/G3) histological grade (p =
0.011) and negativity of progesterone receptor status (p =
0.002) (Table 1). These strong correlations are demon-
strated in Figure 6. In a stratified univariate analysis, the
prognostic value of nuclear YB-1 detection became even
more pronounced in the clinically important subgroup of
stage pT1/T2 tumors, representing ~80% of all diagnosed
carcinomas, and breast tumors with negative progester-
one receptor status (Figures 6 and 7). While pT1 tumours
exhibit no prominent nuclear YB-1 staining (Figure 7A),Page 7 of 17
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tumours (B). In a similar comparison nuclear YB-1 pro-
tein was not detectable in most progesterone receptor pos-
itive breast tumours (Figure 7C), while there was
prominent nuclear YB-1 staining in most tumors with
negative progesterone receptor status (D).
Cox regression models including factors possibly influ-
encing tumor-related survival and recurrence-free survival
in relation to nuclear YB-1 expression were applied. As
could be expected due to the size of our cohort, this anal-
ysis failed to demonstrate significance for nuclear YB1
detection as an independent prognostic marker (Table 2).
Subsequently we analyzed nuclear YB-1 expression with
respect to the molecular breast cancer subtypes defined by
Perou and Sorlie [44,45]. A multiple logistic regression
model was calculated with nuclear YB-1 expression as tar-
get variable and CK5/6, ER and HER2 as covariates (Table
3). None of the tested covariates remained significant; i.e.,
none of the covariates was significantly correlated with
nuclear YB-1 expression, arguing that YB-1 is not selec-
tively expressed in a specific molecular subtype of breast
cancer.
Discussion
Major challenges in cancer diagnostics relate to early
detection of malignant tissue and the possibility to predict
the rate of disease progression and sensitivity to chemo-
therapy. Regarding all these issues the Y-box protein-1
may gain a prominent role, given that (i) it has an onco-
genic property with induction of breast tumors in 100%
of transgenic animals overexpressing YB-1 in the mam-
Immunohistochemical comparison of different YB-1 antibodies in human invasive breast cancerFigure 3
Immunohistochemical comparison of different YB-1 antibodies in human invasive breast cancer. While the pro-
liferation marker Ki67 is strongly expressed in a defined fraction of breast tumor cells there is no concordance to the expres-
sion pattern of YB-1. The three YB-1 antibodies present very similar expression patterns. However, while the two established 
polyclonal YB-1 antibodies (#1 is against an N-terminal epitope and available from antibodies-online; #2 has been established by 
Janz et al. [1]) predominantly detect cytoplasmic YB-1 expression, the newly characterized monoclonal YB-1 antibody Mab F-
E2G5 is able to detect nuclear YB-1 besides less abundant expression in the cytoplasm.
patient 2patient 1
Ki67
YB-1 Ab 
#1 (polycl.)
YB-1 Ab 
#2 (polycl.)
YB-1 
Mab 
F-E2G5 
100x 300x 100x 300xPage 8 of 17
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Expression of YB-1 in normal breast tissue, non-invasive and invasive breast cancerFigure 4
Expression of YB-1 in normal breast tissue, non-invasive and invasive breast cancer. (A) Only weak cytoplasmic 
YB-1 staining is detectable in normal breast tissue. (B) Scale-up of specimen shown in A. The magnification demonstrates weak 
YB-1 expression in luminal-epithelial breast cells. (C) Moderate YB-1 expression in a ductal carcinoma in situ (DCIS) of the 
breast. (D) Scale-up of specimen shown in C. (E) Invasive ductal breast cancer with abundant nuclear YB-1 expression. (F) 
Scale-up of specimen shown in E. Magnifications: A, C, E: 100×; B, D, F: 400×.
A
FE
D
B
C D
BMC Cancer 2009, 9:410 http://www.biomedcentral.com/1471-2407/9/410mary gland [23], (ii) analyses of dysplasia-associated
lesions in colitis ulcerosa patients reveal that lesions with
increased cancer risk are distinguishable due to their YB-1
expression pattern [46], (iii) several reports on breast can-
cer indicate that YB-1 expression levels are strongly predic-
tive for relapse rates and negatively correlate with disease
free survival [6,34,36,47-50], and (iv) YB-1 upregulated P-
glycoprotein expression. To date, however, no clear-cut
standard for the assessment of YB-1 expression levels is
available. In most immunohistochemical analyses overall
expression levels have been scored in cancer tissues. Janz
et al. even included the YB-1 expression within the adja-
cent tissue for analyses, which profoundly improved the
predictive value on relapse-free survival [1].
One of the major obstacles towards a unifying scoring sys-
tem in cancer tissue is the lack of a common expression
pattern observed with diverse antibodies directed against
YB-1. Most antibodies provide a highly specific staining
pattern that is confined to the cytoplasm with complete
absence within the nuclear compartment, as also reported
in the most recent and largest study performed hitherto
Table 1: Clinico-pathological and immunohistochemical parameters in relation to YB-1 immunoreactivity, and univariate analysis of 
factors regarding tumor-related and recurrence-free surival
Variable Categorization Nuclear YB-1 immunoreactivity Tumor-related death Tumor recurrence
n analyzable neg. pos. p* n events p† n events p†
Clinico-pathological data:
Age at diagnosis
<50 years 51 43 8 0.036 51 9 0.0064 51 16 0.1895
≥ 50 years 108 74 34 108 45 102 42
Tumor stage
pT1 40 35 5 0.004 40 4 <0.0001 39 5 0.0001
pT2 83 63 20 83 28 81 34
pT3 10 4 6 10 4 9 4
pT4 26 15 11 26 18 24 15
Lymph node status
pN0 75 60 15 0.101 75 11 <0.0001 74 13 <0.0001
pN1-3 80 54 26 80 41 76 42
Histologic grade
G1 17 16 1 0.011 17 4 0.0047 17 4 <0.0001
G2 69 55 14 69 17 65 16
G3 73 46 27 73 33 71 38
Multifocality
unifocal tumor 141 104 37 1.000 141 45 0.0903 136 49 0.0683
multifocal tumor 18 13 5 18 9 17 9
Histologic type
ductal 125 93 32 0.710 125 43 0.9302 123 49 0.5730
lobular 16 11 5 16 5 14 4
other 15 10 5 15 5 13 4
Immunohistochemistry (IHC):
Estrogen receptor status
negative 42 30 12 1.000 42 19 0.0129 42 24 0.0026
positive 96 69 27 96 25 92 27
Progesterone receptor status
negative 98 63 35 0.002 98 40 0.0045 93 44 0.0019
positive 46 41 5 46 8 46 9
Cytokeratin 5/6 IHC
negative (0) 118 85 33 0.540 118 34 0.0100 114 38 0.0349
positive (1+-3+) 41 32 9 41 20 39 20
TP53 IHC
<10% 85 62 23 1.000 85 28 0.3823 82 28 0.4422
≥ 10% 48 31 17 48 18 46 19
HER2 IHC
negative (0-1+) 108 83 25 1.000 108 28 0.0081 102 31 0.0008
positive (2+-3+) 35 21 14 35 18 35 20
* Fisher's exact test (two-sided), bold face representing significant data.
† Log rank test (two-sided), bold face representing significant data.Page 10 of 17
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YB-1, that relate to oncogenic transformation, cell prolif-
eration and drug resistance, must take place within the
nuclear compartment. These are accompanied by altered
gene transcription as well as chromosomal instability
[18,20,23]. Thus, it is conceivable that a sensitive detec-
tion system and valid predictive testing must include such
information, which is also reiterated by the observation of
nuclear YB-1 being associated with P-glycoprotein expres-
sion and drug resistance [8,11]. It becomes even more
complex when one envisions that YB-1 is a quite abun-
dant cytoplasmic protein and has been detected in the
nucleus in non-transformed cells as well, when tissue is
fixed in Carnoys fixative [43]. The question is therefore,
how these inconsistencies may be reconciled. One answer
may be that YB-1 in cancer tissue has a different antigenic-
ity due to post-translational modifications, e.g. phospho-
rylation of serine 102 [27]. In line with this interpretation
is the observation of nuclear as well as cytoplasmic YB-1
in most cells using immunoblotting and senescence of
cells with YB-1 knock-out [18,51]. Alternatively, cleavage of
YB-1 within the protein C-terminus, as proposed before
via the 20S proteasome [52,53], may render epitopes of
YB-1 accessible for antibodies and result in positive
immunodetection. Sorokin et al. have nicely demon-
strated that the cleaved N-terminal fragment itself may
shuttle to the nucleus and predict chemoresistance,
whereas the overall full-length YB-1 expression level was
unchanged in chemotherapy resistant versus chemosensi-
tive cells. Attempts to explain the hidden secret beyond
the different detection patterns observed already hint at
the difficulties that the design and establishment of a
monoclonal antibody to detect YB-1 faces.
In this report, we describe the generation of a monoclonal
YB-1 antibody, termed F-E2G5, which detects YB-1 in for-
maldehyde-fixed paraffin-embedded tissues. Specificity of
YB-1 detection by this antibody was confirmed by immu-
noblotting with YB-1-GFP fusion protein and ELISA. One
detected epitope must reside within the central domains
encompassing amino acids 21-147, a second one within
domains aa146-172. Notably, using this antibody endog-
enous YB-1 protein is not detected by immunoblotting,
likely due to its "misfolding" under the given conditions.
Likely, that the GFP-tag within the protein C-terminus sta-
bilizes the recognized epitope(s) for detection by western
blotting. A non-specific band detected under some immu-
noblotting conditions does not seem to be of relevance for
the performed immunohistochemistry, given that tissue
specimens from healthy breast tissue do not demonstrate
A and B: Distribution of time (months) to tumor-related death (A) and tumor recurrence (B) among breast cancer patients with negative and positive YB-1 immunoreactivity as estimated by the meth d of Kaplan and MeierFigur  5
A and B: Distribution of time (months) to tumor-related death (A) and tumor recurrence (B) among breast 
cancer patients with negative and positive YB-1 immunoreactivity as estimated by the method of Kaplan and 
Meier.
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A -- D: Distribution of time (months) to tumor-related death among the various subgroups (A, pT1-2; B, pT3-4; C, negative progesterone recept r status; D; posi ive pr gesterone receptor status) of breast cancer patients with negative and positive YB 1 immu oreactivity as stimated by the method f Kaplan nd MeierFigure 6
A -- D: Distribution of time (months) to tumor-related death among the various subgroups (A, pT1-2; B, pT3-
4; C, negative progesterone receptor status; D; positive progesterone receptor status) of breast cancer 
patients with negative and positive YB-1 immunoreactivity as estimated by the method of Kaplan and Meier.
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BMC Cancer 2009, 9:410 http://www.biomedcentral.com/1471-2407/9/410immunopositivity with Mab F-E2G5 and correlation
results indicate that the outcome correlates with a nuclear
staining pattern.
We have used this antibody to analyze YB-1 expression in
a large and clinically well characterized collection of
breast cancer specimens [41] that has previously been suc-
cessfully used to define novel breast tumor markers [40].
Unlike Abba et al. [54] who described an absence of YB-1
mRNA expression in DCIS compared to normal tissues,
we found an increased cytoplasmic concentration of YB-1
protein in six of eight analyzed DCIS compared to normal
tissue. In our study, nuclear YB-1 expression was restricted
to invasive ductal carcinomas. Conversely, tissue sections
Representative tissue microarray staining results illustrating YB-1 expression in relation to tumor stage (A and B) and proges-terone receptor tatus (C and D)Figure 7
Representative tissue microarray staining results illustrating YB-1 expression in relation to tumor stage (A 
and B) and progesterone receptor status (C and D). A and B: While YB-1 staining in small (pT1) tumors is predomi-
nantly cytoplasmic (A), large (pT4) tumors preferentially show a distinct condensation of YB-1 signal in the nuclei of tumor 
cells (B). C and D: In breast tumors with positive progesterone receptor status (C) YB-1 expression is predominantly cytoplas-
mic, while tumors that lost progesterone receptor expression (D) exhibit prominent nuclear YB-1 expression.
A B
DC
pT1 pT4
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nuclear expression of YB-1. Concordantly with these
observations, nuclear expression of YB-1 in invasive breast
cancer was significantly associated with overall survival (p
= 0.0046). In our cohort this correlation was more predic-
tive as observed by Janz et al. [1], who found a less tight
association between YB-1-linked tumor aggressiveness
and poor clinical outcome (p = 0.011).
So far we are the first group that describes a correlation
between nuclear YB-1 expression and increased tumor
grading (p = 0.011) and tumor stage (p = 0.004) in breast
cancer. Although this does not necessarily reflect a causal
relationship, it emphasizes the role of YB-1 as predictive
marker. In non-small lung cancer and ovarian cancer and
by applying polyclonal antibodies, other groups
described an apparent link between YB-1 positivity in the
nucleus and tumor staging. However, they did not find
any correlation between YB-1 positivity and tumor grade
in these entities [3,55,56].
A further finding of our study is the highly significant cor-
relation between nuclear YB-1 expression and negativity
of the progesterone receptor status (p = 0.002), which has
not been described so far. Since YB-1 has been directly
linked to intrinsic or acquired resistance to chemotherapy
and thus might be responsible for failure of current treat-
ment regimens, these findings implicate an interesting
opportunity for the selection of chemotherapy resistant
breast cancer patients out of the whole cohort of patients.
ER-positive/PR-negative breast cancers are known to
respond less well to selective ER modulator (SERM) ther-
apy than ER-positive/PR-positive tumors [57]. Therefore
YB-1 expressing breast cancer may have a general ten-
dency to be hormone refractory, their relative neoplastic
potential thus requiring chemotherapy, even if the tumors
are of small size, low grade or estrogen receptor positive.
Table 2: Multivariate Cox regression analysis of factors possibly influencing tumor-related survival and recurrence-free survival
Tumor-related survival Recurrence-free survival
Name Variables Categorisation Global Stepwise reverse selection† Global Stepwise reverse selection†
p* Hazard 
ratio
95% 
Confidence 
interval
p p* Hazard 
ratio
95% 
Confidence 
interval
p
Model with dichotomous covariables
T Tumor stage 0 pT1-2 0.402 - 0.153 -
1 pT3-4
N Lymp node 
status
0 pN0 0.002 5.050 2.264-11.267 <0.001 0.038 2.934 1.303-6.607 0.009
1 pN1-3
G Histologic 
grade
0 G1-2 0.136 1.875 0.946-3.715 0.072 0.007 3.188 1.442-7.052 0.004
1 G3
ER Estrogen 
receptor 
status
0 negative 0.168 0.420 0.213-0.829 0.012 0.047 0.357 0.173-0.733 0.005
1 positive
HER2 HER2 IHC 0 negative (0-1+) 0.386 - 0.045 2.164 1.019-4.594 0.045
1 positive (2+-3+)
CK5/6 Cytokeratin 
5/6 IHC
0 negative (0) 0.085 - 0.305 -
1 positive (1+-3+)
TP53 TP53 IHC 0 <10% 0.607 - 0.043 0.529 0.256-1.092 0.085
1 ≥ 10%
YB1 YB1 IHC 0 negative (0) 0.530 - 0.738 -
1 positive 
(1+-3+)
Table 3: Multiple logistic regression model. 
Estimate Std. Error t value Pr(>| t|)
(Intercept) -1.187 0.4558 -2.603 0.009
CK56 0.032 0.2460 0.131 0.896
ER -0.009 0.0452 -0.207 0.836
HER2 0.226 0.1577 1.434 0.152
Null Deviance: 170.1; Residual Deviance: 167.8; AIC: 175.8; Degrees 
of Freedom: 146
The estimate for the regression coefficients show the change in YB-1 
corresponding to a unit change in the corresponding marker (ER, 
HER2, CK5/6), conditional on the other markers remaining constant. 
No significant correlation can be seen between YB-1 and one of the 
other markers.Page 14 of 17
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more commonly found in ER negative breast tumors
[6,26]. One may explain this with differences in antibody
detection sensitivity, altered epitopes of YB-1 in the
nuclear compartment, with the latter being the more
likely reason.
In our stratified univariate analysis the prognostic value of
nuclear YB-1 expression became even more pronounced
in the clinically important subgroup of stage pT1/T2
tumors and breast tumors with negative progesterone
receptor status, respectively. Routine mammography
screening for breast cancer in women aged 51-70 is
becoming a standard in the European Community. Thus,
the number and frequency of small sized stage pT1/T2
breast tumors detected is steadily increasing. A YB-1
immunohistochemistry-based diagnostic test could help
to identify young patients with small tumors but signifi-
cant risk of relapse. We are confident that this novel mon-
oclonal YB-1 antibody is of great value in performing
prospective studies to establish YB-1 as a tumor marker in
the management of human breast cancer. For this purpose
large confirmative meta-analyses on independent breast
cancer cohorts will be necessary. Therefore we would like
to encourage other academic groups to validate our data
on their own tumor collections.
Conclusion
The newly established monoclonal anti-YB-1 antibody
(clone F-E2G5) is suited to detect nuclear YB-1 expression
and may be of great value for prospective studies to vali-
date YB-1 as a prognostic marker and to adjust treatment
in breast cancer patients.
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